Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Biotech firm Ovid develops Takeda drug
by Michael McCoy
January 23, 2017
| A version of this story appeared in
Volume 95, Issue 4
In a reverse of the usual big pharma-biotech relationship, the New York City-based biotech firm Ovid Therapeutics will help develop a Takeda Pharmaceutical drug for rare pediatric epilepsy. The drug, a small molecule called TAK-935, inhibits the enzyme cholesterol 24-hydroxylase, which may have a role in central nervous system diseases such as epilepsy. In the deal, Takeda received equity in Ovid, which specializes in rare neurological diseases. The two firms will share any profits on a 50-50 basis.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter